spironolactone has been researched along with Cardiomyopathy, Dilated in 35 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Cardiomyopathy, Dilated: A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.
| Excerpt | Relevance | Reference |
|---|---|---|
| "While median time to cardiac death in the spironolactone group was not statistically significantly different than that in the placebo group, adding spironolactone to conventional therapy resulted in reduced occurrence of AF." | 9.51 | Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy. ( Chambers, H; Fonfara, S; Laskary, A; O'Sullivan, ML, 2022) |
| " We studied the effects of eplerenone, a novel aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy after autoimmune myocarditis." | 7.73 | Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy. ( Aizawa, Y; Kodama, M; Ma, M; Tachikawa, H; Takahashi, T; Wahed, MI; Watanabe, K; Yamaguchi, K, 2005) |
| "Atrial fibrosis caused by chronic CHF is reduced by spironolactone." | 7.73 | Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. ( Beaufils, P; Deangelis, N; Delcayre, C; Hatem, SN; Leenhardt, A; Milliez, P; Robidel, E; Rucker-Martin, C; Vicaut, E, 2005) |
| "Ventricular arrhythmia was recognized as the most common cause of death in this population." | 6.69 | Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. ( Coelho, O; Gruppi, CJ; Mady, C; Mansur, A; Maranhão, M; Ramires, FJ; Ramires, JA, 2000) |
| "While median time to cardiac death in the spironolactone group was not statistically significantly different than that in the placebo group, adding spironolactone to conventional therapy resulted in reduced occurrence of AF." | 5.51 | Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy. ( Chambers, H; Fonfara, S; Laskary, A; O'Sullivan, ML, 2022) |
| " The effects of the mineralocorticoid receptor antagonist spironolactone on left ventricular (LV) function and chamber stiffness associated with myocardial fibrosis were investigated in mildly symptomatic patients with idiopathic dilated cardiomyopathy (DCM)." | 5.11 | Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. ( Amano, T; Asano, H; Ichihara, S; Iino, S; Isobe, S; Izawa, H; Kato, T; Murase, Y; Murohara, T; Nagata, K; Noda, A; Obata, K; Ohshima, S; Okumura, K; Yokota, M, 2005) |
| "To identify the effects of diuretic agents on adverse cardiac remodeling in CHF, this study was carried out, where we have compared the effects of torasemide and spironolactone in a rat model of dilated cardiomyopathy induced by porcine cardiac myosin-mediated experimental autoimmune myocarditis." | 3.85 | Comparative evaluation of torasemide and spironolactone on adverse cardiac remodeling in a rat model of dilated cardiomyopathy. ( Arumugam, S; Harima, M; Karuppagounder, V; Nakamura, M; Sone, H; Sreedhar, R; Suzuki, H; Watanabe, K, 2017) |
| " We studied the effects of eplerenone, a novel aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy after autoimmune myocarditis." | 3.73 | Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy. ( Aizawa, Y; Kodama, M; Ma, M; Tachikawa, H; Takahashi, T; Wahed, MI; Watanabe, K; Yamaguchi, K, 2005) |
| "Atrial fibrosis caused by chronic CHF is reduced by spironolactone." | 3.73 | Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. ( Beaufils, P; Deangelis, N; Delcayre, C; Hatem, SN; Leenhardt, A; Milliez, P; Robidel, E; Rucker-Martin, C; Vicaut, E, 2005) |
| "Reverse ventricular remodeling obtained with carvedilol, ramipril/candesartan, and spironolacton is associated with decreases in left ventricular end-diastolic volume, left ventricular end-systolic volume, tenascin-C levels, and NT-proBNP levels." | 2.78 | Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy. ( Akpek, M; Kaya, EG; Kaya, MG; Lam, YY; Sarli, B; Topsakal, R, 2013) |
| "Ivabradine is a safe and effective drug in reducing resting heart rate, improving NYHA functional class without undesirable effects on conduction parameters or ectopic activity." | 2.76 | Ivabradine, a novel heart rate slower: is it a sword of double blades in patients with idiopathic dilated cardiomyopathy? ( Alabd, A; Gamal, A; Rayan, M; Tawfik, M, 2011) |
| "Ventricular arrhythmia was recognized as the most common cause of death in this population." | 2.69 | Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. ( Coelho, O; Gruppi, CJ; Mady, C; Mansur, A; Maranhão, M; Ramires, FJ; Ramires, JA, 2000) |
| " On long term evaluation in an open design (Phase II), wherein Phase I participants continued Terminalia Arjuna in fixed dosage (500 mg 8-hourly) in addition to flexible diuretic, vasodilator and digitalis dosage for 20-28 months (mean 24 months) on outpatient basis, patients showed continued improvement in symptoms, signs, effort tolerance and NYHA Class, with improvement in quality of life." | 2.68 | Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. ( Bharani, A; Bhargava, KD; Ganguly, A, 1995) |
| "Dilated cardiomyopathy is a syndrome characterized by dilatation and impaired function of one or both ventricles and represents the most common heart failure entity requiring heart transplantation." | 2.42 | Up to date in pharmacological treatment of dilated cardiomyopathy. ( Ghiorghiu, I; Ginghina, C; Serban, M; Stoian, I; Teodorescu, A; Wohlfart, K, 2004) |
| "Eleven cases of dilated cardiomyopathy have been diagnosed and treated in captive Livingstone fruit bats ( Pteropus livingstonii) in the United Kingdom over the past 7 yr." | 1.46 | MEDICAL MANAGEMENT OF DILATED CARDIOMYOPATHY IN LIVINGSTONE FRUIT BATS ( PTEROPUS LIVINGSTONII). ( Barbon, AR; Barrows, M; Borgeat, K; Day, C; Drane, AL; Hayward, N; Killick, R; Naylor, A; Routh, A; Saunders, R; Sewell, D; Studies, PGCEA; Wilkie, L, 2017) |
| "Echocardiography showed 73% dilated cardiomyopathy; 83% showed moderate to severe LV systolic dysfunction (mean EF 36." | 1.43 | Clinical and echocardiographic characteristics and outcomes in congestive heart failure at the Hospital of The State University of Haiti. ( Malebranche, R; Morisset, PH; Raphael, NA; Tabou Moyo, C; Wilentz, JR, 2016) |
| "Treatment with eplerenone (100 mg/kg/d) attenuated left ventricular hypertrophy and fully prevented fibrosis, dilatation, and failure." | 1.40 | Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation. ( Baba, HA; Frantz, S; Gaßner, B; Kuhn, M; Nakagawa, H; Nikolaev, VO; Oberwinkler, H; Saito, Y; Umbenhauer, S; Wagner, H, 2014) |
| "Outcome of dilated cardiomyopathy (DCM) has markedly improved due to ACE-inhibitors, beta-blockers and implantable defibrillators over the last decades." | 1.35 | Outcome of patients with dilated cardiomyopathy in a contemporary Swiss population. ( Osswald, S; Schaer, B; Sticherling, C; Vischer, A, 2009) |
| "Their mitral regurgitation (MR) is a result of left ventricular (LV) geometrical distortion." | 1.33 | Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair. ( Bolling, SF; Geltz, A; Spoor, MT, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.86) | 18.2507 |
| 2000's | 20 (57.14) | 29.6817 |
| 2010's | 12 (34.29) | 24.3611 |
| 2020's | 2 (5.71) | 2.80 |
| Authors | Studies |
|---|---|
| Lawson, MA | 2 |
| Hansen, DE | 1 |
| Gupta, DK | 1 |
| Bell, SP | 2 |
| Adkisson, DW | 2 |
| Mallugari, RR | 1 |
| Sawyer, DB | 2 |
| Ooi, H | 2 |
| Kronenberg, MW | 2 |
| Laskary, A | 1 |
| Fonfara, S | 1 |
| Chambers, H | 1 |
| O'Sullivan, ML | 1 |
| Arumugam, S | 1 |
| Sreedhar, R | 1 |
| Karuppagounder, V | 1 |
| Harima, M | 1 |
| Nakamura, M | 2 |
| Suzuki, H | 1 |
| Sone, H | 1 |
| Watanabe, K | 2 |
| Killick, R | 1 |
| Barbon, AR | 1 |
| Barrows, M | 1 |
| Routh, A | 1 |
| Saunders, R | 1 |
| Day, C | 1 |
| Studies, PGCEA | 1 |
| Naylor, A | 1 |
| Hayward, N | 1 |
| Sewell, D | 1 |
| Borgeat, K | 1 |
| Drane, AL | 1 |
| Wilkie, L | 1 |
| Sarli, B | 1 |
| Topsakal, R | 1 |
| Kaya, EG | 1 |
| Akpek, M | 1 |
| Lam, YY | 1 |
| Kaya, MG | 1 |
| Vizzardi, E | 1 |
| Pina, PD | 1 |
| Caretta, G | 1 |
| Bonadei, I | 1 |
| Sciatti, E | 1 |
| Lombardi, C | 1 |
| D'Aloia, A | 1 |
| Curnis, A | 1 |
| Metra, M | 1 |
| Nakagawa, H | 1 |
| Oberwinkler, H | 1 |
| Nikolaev, VO | 1 |
| Gaßner, B | 1 |
| Umbenhauer, S | 1 |
| Wagner, H | 1 |
| Saito, Y | 1 |
| Baba, HA | 1 |
| Frantz, S | 1 |
| Kuhn, M | 1 |
| Wang, L | 1 |
| Baumwol, J | 1 |
| Lam, K | 1 |
| Maiorana, AJ | 1 |
| Thomason, JD | 1 |
| Rapoport, G | 1 |
| Fallaw, T | 1 |
| Calvert, CA | 1 |
| Malebranche, R | 1 |
| Tabou Moyo, C | 1 |
| Morisset, PH | 1 |
| Raphael, NA | 1 |
| Wilentz, JR | 1 |
| Barison, A | 1 |
| Aquaro, GD | 1 |
| Passino, C | 1 |
| Falorni, M | 1 |
| Balbarini, A | 1 |
| Lombardi, M | 1 |
| Pasquali, L | 1 |
| Emdin, M | 1 |
| Siciliano, G | 1 |
| Altenberger, H | 1 |
| Stöllberger, C | 1 |
| Finsterer, J | 1 |
| Vischer, A | 1 |
| Osswald, S | 1 |
| Sticherling, C | 1 |
| Schaer, B | 1 |
| Parker, T | 1 |
| Tsuda, E | 1 |
| Matsuo, M | 1 |
| Sakaguchi, H | 1 |
| Hayashi, T | 1 |
| Hosoda, K | 1 |
| Miyazaki, A | 1 |
| Veliotes, DG | 1 |
| Norton, GR | 1 |
| Correia, RJ | 1 |
| Strijdom, H | 1 |
| Badenhorst, D | 1 |
| Brooksbank, R | 1 |
| Woodiwiss, AJ | 1 |
| Rayan, M | 1 |
| Tawfik, M | 1 |
| Alabd, A | 1 |
| Gamal, A | 1 |
| Goineau, S | 2 |
| Pape, D | 3 |
| Guillo, P | 2 |
| Ramée, MP | 2 |
| Bellissant, E | 3 |
| Kasama, S | 1 |
| Toyama, T | 1 |
| Kumakura, H | 1 |
| Takayama, Y | 1 |
| Ichikawa, S | 1 |
| Suzuki, T | 1 |
| Kurabayashi, M | 1 |
| Tsutamoto, T | 1 |
| Wada, A | 1 |
| Ohnishi, M | 1 |
| Tsutsui, T | 1 |
| Ishii, C | 1 |
| Ohno, K | 1 |
| Fujii, M | 1 |
| Matsumoto, T | 1 |
| Yamamoto, T | 1 |
| Takayama, T | 1 |
| Dohke, T | 1 |
| Horie, M | 1 |
| Wahed, MI | 1 |
| Ma, M | 1 |
| Yamaguchi, K | 1 |
| Takahashi, T | 1 |
| Tachikawa, H | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Ginghina, C | 1 |
| Teodorescu, A | 1 |
| Stoian, I | 1 |
| Serban, M | 1 |
| Ghiorghiu, I | 1 |
| Wohlfart, K | 1 |
| Satoh, M | 1 |
| Akatsu, T | 1 |
| Shimoda, Y | 1 |
| Segawa, I | 1 |
| Hiramori, K | 1 |
| Belenkov, IuN | 1 |
| Belianko, IE | 1 |
| Gerasimova, VV | 1 |
| Dolotov, VK | 1 |
| Konstantinov, BA | 1 |
| Koroteev, AV | 1 |
| Kulagina, TIu | 1 |
| Mareev, VIu | 1 |
| Rebunenkov, GV | 1 |
| Sandrikov, VA | 1 |
| Skvortsov, AA | 1 |
| Sychev, AV | 1 |
| Tereshchenko, SN | 1 |
| Khovrin, VV | 1 |
| McAlister, FA | 1 |
| Tu, JV | 1 |
| Newman, A | 1 |
| Lee, DS | 1 |
| Kimber, S | 1 |
| Cujec, B | 1 |
| Armstrong, PW | 1 |
| Milliez, P | 1 |
| Deangelis, N | 1 |
| Rucker-Martin, C | 1 |
| Leenhardt, A | 1 |
| Vicaut, E | 1 |
| Robidel, E | 1 |
| Beaufils, P | 1 |
| Delcayre, C | 1 |
| Hatem, SN | 1 |
| Nattel, S | 1 |
| Izawa, H | 1 |
| Murohara, T | 1 |
| Nagata, K | 1 |
| Isobe, S | 1 |
| Asano, H | 1 |
| Amano, T | 1 |
| Ichihara, S | 1 |
| Kato, T | 1 |
| Ohshima, S | 1 |
| Murase, Y | 1 |
| Iino, S | 1 |
| Obata, K | 1 |
| Noda, A | 1 |
| Okumura, K | 1 |
| Yokota, M | 1 |
| Spoor, MT | 1 |
| Geltz, A | 1 |
| Bolling, SF | 1 |
| Laviolle, B | 1 |
| Turlin, B | 1 |
| Bharani, A | 1 |
| Ganguly, A | 1 |
| Bhargava, KD | 1 |
| Ramires, FJ | 1 |
| Mansur, A | 1 |
| Coelho, O | 1 |
| Maranhão, M | 1 |
| Gruppi, CJ | 1 |
| Mady, C | 1 |
| Ramires, JA | 1 |
| Elliott, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Aldosterone on Energy Starvation in Heart Failure[NCT00574119] | Phase 4 | 16 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6MWT assesses distance walked over 6 minutes (NCT00574119)
Timeframe: 6 months
| Intervention | meters (Median) |
|---|---|
| Results With Spironolactone | 542 |
6MWT assesses distance walked over 6 minutes (NCT00574119)
Timeframe: baseline
| Intervention | meters (Median) |
|---|---|
| Results With Spironolactone | 521 |
T1=left ventricular relaxation rate on magnetic resonance imaging, which is correlated with interstitial fibrosis. (NCT00574119)
Timeframe: baseline and 6 months
| Intervention | msec (Mean) |
|---|---|
| Results With Spironolactone | 6 |
WMI=[left ventricular stroke work/decay rate of 11C-acetate] (NCT00574119)
Timeframe: 6 months
| Intervention | (x10^6), mL x mm Hg/m^2 (Median) |
|---|---|
| Results With Spironolactone | 5.4 |
WMI=[left ventricular stroke work/decay rate of 11C-acetate] (NCT00574119)
Timeframe: baseline
| Intervention | (x10^6), mL x mm Hg/m^2 (Median) |
|---|---|
| Results With Spironolactone | 7.4 |
The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. Each question is scored from 0 (none or not applicable) to 5 (very much). Total scores range from 0-105. Low scores indicate less adverse impact, while higher scores reflect more adverse impact of heart failure. (NCT00574119)
Timeframe: baseline
| Intervention | score on a scale (Median) |
|---|---|
| Results With Spironolactone | 54 |
The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. Each question is scored from 0 (none or not applicable) to 5 (very much). Total scores range from 0-105. Low scores indicate less adverse impact, while higher scores reflect more adverse impact of heart failure. (NCT00574119)
Timeframe: 6 months
| Intervention | score on a scale (Median) |
|---|---|
| Results With Spironolactone | 22 |
MPRI =calculated myocardial perfusion reserve index based on Gadolinium accretion into myocardium. MPRI was calculated as the ratio of stress/rest relative perfusion upslope, corrected for LV cavity upslope. (NCT00574119)
Timeframe: 6 months
| Intervention | MPRI (Mean) |
|---|---|
| Results With Spironolactone | 1.80 |
MPRI =calculated myocardial perfusion reserve index based on Gadolinium accretion into myocardium. MPRI was calculated as the ratio of stress/rest relative perfusion upslope, corrected for LV cavity upslope. (NCT00574119)
Timeframe: baseline
| Intervention | MPRI (Mean) |
|---|---|
| Results With Spironolactone | 1.72 |
2 reviews available for spironolactone and Cardiomyopathy, Dilated
| Article | Year |
|---|---|
Up to date in pharmacological treatment of dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Cardiomyopa | 2004 |
Cardiomyopathy. Diagnosis and management of dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme | 2000 |
8 trials available for spironolactone and Cardiomyopathy, Dilated
| Article | Year |
|---|---|
Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy.
Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Death; Dog Diseases; Dogs; Euthanasia, Animal | 2022 |
Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Carbazoles; Cardiomyopathy, Dilat | 2013 |
The effect of aldosterone-antagonist therapy on aortic elastic properties in patients with nonischemic dilated cardiomyopathy.
Topics: Aged; Aorta; Blood Pressure; Cardiomyopathy, Dilated; Elasticity; Female; Humans; Male; Middle Aged; | 2015 |
Ivabradine, a novel heart rate slower: is it a sword of double blades in patients with idiopathic dilated cardiomyopathy?
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Benzazepines; Carbazoles; C | 2011 |
Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy.
Topics: Adult; Aged; Aged, 80 and over; Cardiomyopathy, Dilated; Echocardiography; Female; Follow-Up Studies | 2003 |
Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study.
Topics: Adult; Aged; Biopsy; Cardiomyopathy, Dilated; Female; Fibrosis; Heart Failure; Humans; Male; Middle | 2005 |
Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure.
Topics: Adult; Aged; Cardiomyopathy, Dilated; Chemotherapy, Adjuvant; Chronic Disease; Coronary Disease; Cro | 1995 |
Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy.
Topics: Analysis of Variance; Antihypertensive Agents; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Death, | 2000 |
25 other studies available for spironolactone and Cardiomyopathy, Dilated
| Article | Year |
|---|---|
Modification of ventriculo-arterial coupling by spironolactone in nonischemic dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volu | 2021 |
Comparative evaluation of torasemide and spironolactone on adverse cardiac remodeling in a rat model of dilated cardiomyopathy.
Topics: Animals; Autoimmunity; Biomarkers; Cardiac Myosins; Cardiomyopathy, Dilated; Disease Models, Animal; | 2017 |
MEDICAL MANAGEMENT OF DILATED CARDIOMYOPATHY IN LIVINGSTONE FRUIT BATS ( PTEROPUS LIVINGSTONII).
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Zoo; Cardiomyopathy, Dilated; Cardiotoni | 2017 |
Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.
Topics: Animals; Atrial Natriuretic Factor; Blotting, Western; Cardiomyopathy, Dilated; Connective Tissue Gr | 2014 |
Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Heart Ventricles; Humans; Magneti | 2014 |
Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Heart Ventricles; Humans; Magneti | 2014 |
Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Heart Ventricles; Humans; Magneti | 2014 |
Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Heart Ventricles; Humans; Magneti | 2014 |
Successful explant of a continuous-flow left ventricular assist device after two years of circulatory support.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiomyopathy, Dilated; Diuretics; Exe | 2014 |
The influence of enalapril and spironolactone on electrolyte concentrations in Doberman pinschers with dilated cardiomyopathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathy, Dilated; Cohort Studies; Dog Dise | 2014 |
Clinical and echocardiographic characteristics and outcomes in congestive heart failure at the Hospital of The State University of Haiti.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Age Distribution; Aged; Aged, 80 and over; Angiotens | 2016 |
Cardiac magnetic resonance imaging and management of dilated cardiomyopathy in a Duchenne muscular dystrophy manifesting carrier.
Topics: Adult; Biomarkers; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Child; Creatine Kinase; Disease | 2009 |
Isolated left ventricular hypertrabeculation/noncompaction in a Turner mosaic with male phenotype.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiomyopathy, | 2009 |
Outcome of patients with dilated cardiomyopathy in a contemporary Swiss population.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Card | 2009 |
Case of the month. Idiopathic dilated cardiomyopathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Angiography; Angiotensin-Converting | 2009 |
Combined amiodarone and low-dose carvedilol treatment for severe heart failure in childhood.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dos | 2010 |
Impact of aldosterone receptor blockade on the deleterious cardiac effects of adrenergic activation in hypertensive rats.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Blood Pressure; Cardiomyopathy, Dilated; Hypertension; | 2010 |
Combined effects of metoprolol and spironolactone in dilated cardiomyopathic hamsters.
Topics: Animals; Cardiomyopathy, Dilated; Cricetinae; Drug Therapy, Combination; Hemodynamics; Male; Metopro | 2002 |
Combined effects of enalapril and spironolactone in hamsters with dilated cardiomyopathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Cardiomyopathy, Dilated; Cricetinae; | 2003 |
Transcardiac increase in tumor necrosis factor-alpha and left ventricular end-diastolic volume in patients with dilated cardiomyopathy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathy, Dilated; Case-Control Studies | 2004 |
Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy.
Topics: Animals; Autoimmune Diseases; Cardiomyopathy, Dilated; Collagen Type III; Dose-Response Relationship | 2005 |
C-reactive protein co-expresses with tumor necrosis factor-alpha in the myocardium in human dilated cardiomyopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; C-Reactive Protei | 2005 |
[Implantation of an extracardiac mesh in the treatment of dilated cardiomyopathy: the TOLK Study (Therapevticheskoe Operativnoe Lechenie Kardiomyopatye)].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Di | 2005 |
How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiotensin-Converting | 2006 |
Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction.
Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Fibrosis; Heart Atria; Heart Failure; Male; M | 2005 |
Aldosterone antagonism and atrial fibrillation: time for clinical assessment?
Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Fibrosis; Heart Failure; Mineralocorticoid Re | 2005 |
Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiomyopathy, Dilated; Combined Modality | 2006 |
Direct effects of 3 combinations of enalapril, metoprolol, and spironolactone on cardiac remodeling in dilated cardiomyopathic hamsters.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathy, Dila | 2006 |